Filtered By:
Condition: Migraine
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 898 results found since Jan 2013.
Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial
CONCLUSIONS: In this double-blind placebo-controlled phase III trial, melatonin did not prevent or significantly improve fatigue and other symptoms in patients with early stage breast cancer undergoing RT. The analysis, showing little evidence of an effect, at mid-recruitment, assured early termination of the trial.PMID:37699115 | DOI:10.1093/oncolo/oyad250
Source: The Oncologist - September 12, 2023 Category: Cancer & Oncology Authors: Nitai D Mukhopadhyay Adam Khorasanchi Sudeep Pandey Srinidhi Nemani Gwendolyn Parker Xiaoyan Deng Douglas W Arthur Alfredo Urdaneta Egidio Del Fabbro Source Type: research
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
CONCLUSIONS: Combination of PAC-1 and TMZ was well tolerated up to 625 mg orally daily and TMZ orally 150 mg/m2/5 days per 28-day cycle. The maximum tolerated dose was not reached. Further dose escalation of PAC-1 in combination with TMZ is advised before conducting a formal prospective efficacy study in this patient population.PMID:37554223 | PMC:PMC10406430 | DOI:10.1093/noajnl/vdad087
Source: Adv Data - August 9, 2023 Category: Epidemiology Authors: Matthias Holdhoff M Kelly Nicholas Richard A Peterson Stefania Maraka Li C Liu James H Fischer Jeffrey S Wefel Timothy M Fan Tracy Vannorsdall Meredith Russell Michaella Iacoboni Theodore M Tarasow Paul J Hergenrother Arkadiusz Z Dudek Oana C Danciu Source Type: research
Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination
CONCLUSIONS: The humoral response against VOCs after the CoronaVac vaccination in CCP was moderately impaired although the vaccine was safe. Age and chemotherapy time seem to be the primary reason for poor response and low serology levels.PMID:37304300 | PMC:PMC10247972 | DOI:10.3389/fimmu.2023.1110755
Source: Cancer Control - June 12, 2023 Category: Cancer & Oncology Authors: Yifei Ma Bocen Chen Yanqi Wang Pengfei Zhu Nianqi Liu Zhiying Zhang Guanqing Zhong Guangzhen Fu Dao Wang Lu Cao Shenrui Bai Youlong Wang Shuqin Chen Xiaolong Wei Jun Lv Ao Zhang Xinjia Wang Source Type: research
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
This report describes the first two clinical studies of OPC-167832: (i) a phase I single ascending dose (SAD) and food effects study in healthy participants; and (ii) a 14-day phase I/IIa multiple ascending dose (MAD; 3/10/30/90 mg QD) and early bactericidal activity (EBA) trial in participants with drug-susceptible pulmonary tuberculosis (TB). OPC-167832 was well tolerated at single ascending doses (10 to 480 mg) in healthy participants and multiple ascending doses (3 to 90 mg) in participants with TB. In both populations, nearly all treatment-related adverse events were mild and self-limiting, with headache and pruritus ...
Source: Antimicrobial Agents and Chemotherapy - May 23, 2023 Category: Microbiology Authors: Rodney Dawson Andreas H Diacon Kim Narunsky Veronique R De Jager Kelly W Stinson Xiaoyan Zhang Yongge Liu Jeffrey Hafkin Source Type: research
Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy
We describe the case of a middle-aged woman with gastric cancer. She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progression, but developed unconsciousness, irritability, and headache shortly after initiation of treatment. Her magnetic resonance imaging in our hospital shows abnormal signals in bilateral frontal parietal occipital lobes with hyperintensities on T2-weighted magnetic resonance imaging and fluid-attenuated inversion recovery imaging, accompanied by the increased value of apparent diffusion coefficient. And T1-weighted images illu...
Source: Cancer Control - May 23, 2023 Category: Cancer & Oncology Authors: LinLin Xie Source Type: research
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
This report describes the first two clinical studies of OPC-167832: (i) a phase I single ascending dose (SAD) and food effects study in healthy participants; and (ii) a 14-day phase I/IIa multiple ascending dose (MAD; 3/10/30/90 mg QD) and early bactericidal activity (EBA) trial in participants with drug-susceptible pulmonary tuberculosis (TB). OPC-167832 was well tolerated at single ascending doses (10 to 480 mg) in healthy participants and multiple ascending doses (3 to 90 mg) in participants with TB. In both populations, nearly all treatment-related adverse events were mild and self-limiting, with headache and pruritus ...
Source: Antimicrobial Agents and Chemotherapy - May 23, 2023 Category: Microbiology Authors: Rodney Dawson Andreas H Diacon Kim Narunsky Veronique R De Jager Kelly W Stinson Xiaoyan Zhang Yongge Liu Jeffrey Hafkin Source Type: research
Primary dedifferentiated chondrosarcoma of the lung with a 4-year history of breast cancer: A case report
CONCLUSION: This case revealed a rare primary DDCS of the lung with a medical history of breast cancer, meaning a worse prognosis and making it more difficult to treat.PMID:37215415 | PMC:PMC10198077 | DOI:10.12998/wjcc.v11.i13.3022
Source: Clinical Lung Cancer - May 22, 2023 Category: Cancer & Oncology Authors: Huan Wen Feng-Jie Gong Jian-Min Xi Source Type: research
Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells
Biochem Pharmacol. 2023 Apr 3:115538. doi: 10.1016/j.bcp.2023.115538. Online ahead of print.ABSTRACTLiver cancer is the most common and frequentlyoccurring cancer. In addition to radiotherapy, chemotherapy and surgery are recommended as part of liver cancer treatment. The efficacy of sorafenib and sorafenib-based combination treatment against tumors has been verified. Although, clinical trials have revealed that some individuals are not sensitive to sorafenib therapy, and current therapeutic approaches are ineffective. Consequently, it is urgent to explore effective drug combinations and innovative techniques for increasin...
Source: Biochemical Pharmacology - April 5, 2023 Category: Drugs & Pharmacology Authors: Meng He Qiuyu Liao Dong Liu Xufang Dai Meihua Shan Mingzhen Yang Yang Zhang Liuyue Zhai Lingxi Chen Li Xiang Mei He Shuhui Li An Chen Liangbo Sun Jiqin Lian Source Type: research
Intrathecal CAR-NK cells infusion for isolated CNS relapse after allogeneic stem cell transplantation: case report
In conclusion, IT CAR-NK cells infusion is a potentially feasible and effective option for patients with CNS relapse, with limited neurological toxicity.PMID:36941630 | DOI:10.1186/s13287-023-03272-0
Source: Cell Research - March 21, 2023 Category: Cytology Authors: Jing Yuan Fuxu Wang Hanyun Ren Source Type: research
Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study
Antimicrob Agents Chemother. 2023 Feb 28:e0151422. doi: 10.1128/aac.01514-22. Online ahead of print.ABSTRACTAnti-SARS-CoV-2 immunoglobulin (human) investigational product (COVID-HIGIV) is a purified immunoglobulin preparation containing SARS-CoV-2 polyclonal antibodies. This single-center clinical trial aimed to characterize the safety and pharmacokinetics of COVID-HIGIV in healthy, adult volunteers. Participants were enrolled to receive one of three doses of COVID-HIGIV (100, 200, 400 mg/kg) or placebo in a 2:2:2:1 randomization scheme. Between 24 December 2020 and 27 July 2021, 28 participants met eligibility and were ra...
Source: Antimicrobial Agents and Chemotherapy - February 28, 2023 Category: Microbiology Authors: Sean T H Liu Mila Mirceta Grace Lin Deborah M Anderson Tarashon Broomes Alina Jen Ashley Abid David Reich Christine Hall Judith A Aberg Source Type: research
